exactly. The need for efficiency in developing effective new therapeutics has never been greater.
|
|
|
- Daniella Evans
- 10 years ago
- Views:
Transcription
1
2 exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research, discovery and development of new therapeutics has never been more important. Now more than ever, Charles River is committed to developing broader, more flexible relationships with our clients, providing tailored approaches to help accelerate and support research into the understanding of disease and the development and delivery of safe and effective new therapies. resources with the changing needs of a complex product development portfolio. With our global network of resources, high-quality products and services, state-of-the-art facilities and our expert staff, we are building a portfolio that provides exactly what our clients need to support their research programs. Our goal is to help accelerate research and drug development programs. Exactly. Our relationships with clients are evolving into strategic partnerships as we aim to become an extension of their internal organizations. From primary research through proof-of-concept, we deliver the capabilities and expertise needed to help balance their internal Our clients are facing a time of unprecedented change. The pressure to produce new, highly effective therapies more cost-efficiently, while meeting safety and regulatory requirements, has never been greater. By strategically supporting our clients with a unique portfolio of products, services, facilities and scientific expertise, we believe we can be part of the solution, partnering with them to accelerate drug development. Researchers are expanding their relationships with Contract Research Organizations like Charles River to help accelerate new compounds efficiently from discovery through the drug development continuum. JAMES C. FOSTER, CHAIRMAN, PRESIDENT AND CEO charles river 1 2
3 discover. With new technologies and an increasing understanding of the complexities of health and disease comes the opportunity to discover innovative therapeutics. Research and discovery requires innovation and flexibility at every stage. The appropriate use of models to identify a target, characterize compound disposition, determine a pathway or mimic a disease is essential to the discovery process. For more than half a century, Charles River has supported primary research needs, pioneering rigorous and exacting standards for animal production including strict biosecurity measures that ensure that our clients around the world receive reliable, predictive models. The key to rapid decision-making lies in high-quality assessment, rapid data availability and analytical expertise. We offer in vitro assays, in vivo screening tools, extensive xenograft and imaging capabilities and laboratory support services to help define and optimize lead candidates prior to the preclinical phase and the costly safety testing required for early-phase clinical trials. With extensive experience in research models, pharmacology and toxicology, combined with unmatched expertise in veterinary science, Charles River provides a high-quality customized approach to support research and discovery programs. Capabilities designed to help accelerate research and discovery: Research Models Discovery and Imaging Services Genetically Engineered Models and Services Surgical Services Research Animal Diagnostic Services Custom Antibody Production We are continually expanding our portfolio to provide comprehensive integrated services that align with our clients program needs and support researchers with the characterization and optimization of lead compounds. charles river 3 4
4 integrate. As newly discovered compounds move through the development process into the clinical phase and then to market, there is a critical need to balance efficacy assessment and patient safety with reduced cycle times. Whether in a single aspect of a study or through a full discoveryto-ind program, our scientists have the expertise to flexibly support and expedite all elements of preclinical work. We can assist with appropriate species selection, pre-ind consultation and toxicology and safety pharmacology study design approaches, supported by extensive laboratory services. and enhance the process, allowing maximum optimization of both internal and external resources and supporting the safe and effective acceleration of compounds through the drug development process. Our team is experienced in designing and conducting pilot and GLPcompliant general and specialty toxicology studies for a variety of compound types. Our involvement in clients preclinical programs allows us to aid in the seamless transition of a compound into Phase I clinical trials. Our consulting and regulatory experts can customize unique programs to navigate from preclinical into clinical development. Broad-based programs complement clients core competencies In addition, our early clinical development experience can aid in appropriate study design, stringent safety assessment and effective participant recruiting, ensuring that participant safety is a priority. Support to safely accelerate drug development: Safety Assessment Broad Specialty Toxicology Experience Early-Phase Clinical Trials Clinical Trial Support Services Therapeutic Area Expertise Regulatory Consulting We can help design and conduct studies to ensure the most efficient use of resources while delivering effective safety assessment programs from preclinical through first-in-human (FIH) clinical trials and beyond. charles river 5 6
5 accelerate. Rapidly obtaining the most accurate and reliable results is essential for safe and efficient quality control and manufacturing. The increasing number of novel biologics in development creates new challenges in the types of testing required to assess the manufacturing process, including the complexities of safety, potency and lot release testing. With a focus on regulatory guidelines, Charles River offers proven testing solutions and programs designed to address each step in the product manufacturing process. Rapid, reliable endotoxin test results are necessary to confirm the timely and safe manufacture of all injectable drugs and implantable devices, and the application of dialysis as well as cellular and nuclear therapeutics. As an extension of our trusted routine LAL testing products, our FDA-licensed Endosafe -PTS is an innovative handheld test system that provides quantitative results in just 15 minutes, with the convenience of portability. The new Endosafe -MCS system offers a complementary highervolume solution for laboratory settings. To meet the research and development needs of clients focused on virus and vaccine production, Charles River offers a comprehensive portfolio of avian products and testing services, including the specific pathogen-free egg. We also provide comprehensive testing, process validation and vaccine manufacturing services to help clients around the world develop and market biopharmaceutical therapies. Our services enable companies to meet regulatory guidelines and ultimately bring their products to market faster and more economically. Supporting our clients quality and manufacturing needs to ensure accurate and reliable results: Avian Products and Services Endotoxin and Microbial Detection Products and Services Biopharmaceutical Services, including: viral clearance, vaccine safety and manufacturing, cell line characterization and cell banking, in vivo biosafety and potency testing, bioassay development We support our clients quality and manufacturing needs through innovative services, products and solutions for in-process and final release testing of drugs, devices and vaccines. charles river 7 8
6 optimize. Expertise, experience, insight, flexible availability of resources exactly what is needed to support efficient research and drug development. Optimizing programs and maximizing resources are essential for today s research and development climate. Precise planning helps clients anticipate and navigate through the many challenges that can adversely affect research, delay development and cause unnecessary expenditure, and even ultimately prevent products from reaching their full market potential. These challenges may be related to animal care activities, drug safety, dose regimen, clinical planning or fundamental strategic approaches to program design. To help anticipate and overcome these hurdles, Charles River offers a range of consulting options and resources, including strategic assistance, regulatory and scientific advice, individualized program management, contract staffing within clients facilities and also veterinary care training. the experience, insight and knowledge necessary to help clients reach strategic milestones. This wealth of experience encompasses multiple disciplines, compound classes and therapeutic areas, enabling clients to leverage this expertise to manage a facility, design and direct focused research and development programs and prepare regulatory documents in a timely and efficient manner. Our goal is to provide exactly what our clients need to fully leverage their core competencies and extend their internal resources by flexibly utilizing ours. Optimizing programs and maximizing resources are essential for today s research and development climate. Our global network of scientific, regulatory and veterinary professionals and highly trained animal caretakers all possess Resources, experience and expertise to enhance our clients capabilities: Consulting and Staffing Services IND/Global Regulatory Consulting Program Management and Strategic Consulting Educational Programs charles river 9 10
7 commitment. The quality of our lives can be impacted by the quality of theirs. Humane care is not only a moral imperative, but a scientific necessity. Research animal models are an important resource that enables us to further our knowledge of living systems and contribute to the discovery and delivery of life-saving drugs and procedures for both humans and animals. In addition to the role we play in helping improve human health, we offer a full range of services to support development of products for animal health. We also continue to seek innovative ways to provide effective testing without relying on traditional research models. Charles River also implemented a global Humane Care Initiative nearly ten years ago. Going beyond the requirements set forth in global, federal and international regulations, this initiative raises awareness of the importance of humane care. Through effective orientation and training, we continually reinforce this culture of caring that has been a passion of Charles River employees for more than 60 years. Treating animals with care and respect can also directly influence the success of a research protocol. For decades we have fostered this culture across our company and around the globe to establish ourselves as a worldwide leader in the compassionate care of research animals. This concern for animal welfare is expressed in one of our core values: We are committed to the humane care of the research animals produced and used in all Charles River activities. As animal caregivers and researchers, we are all responsible for the health and well-being of the animals in our care. charles river 11 12
8 Market Approval NDA/BLA/MAA Submission IND/CTA Filing From the global standardization of our research models to the high standards that we set for our professional team and our state-of-the-art facilities and technologies, we can customize programs to meet the specific research needs of our clients. The Charles River portfolio of capabilities supports primary research and spans each phase of the drug discovery and development process. The breadth and depth of our portfolio allows for the customization of solutions, enabling clients to reduce costs, enhance productivity and increase speed to market, all with the convenience of working with one reliable partner. As pressure for efficiency increases, outsourcing non-core activities can alleviate internal bottlenecks and align internal resources with immediate needs, allowing clients to focus on proprietary drug discovery and go-to-market efforts. In the academic sector, Charles River remains strongly committed to supporting high-quality research through our globally exactly. standardized models and health surveillance programs, as well as our continuing technical support, and veterinary science and animal husbandry training. With approximately 70 facilities in 17 countries, Charles River aims to be the ideal partner for progressing new therapies from research models to humans in a rational, cost-effective and timely manner. Understanding our clients needs for global standards and compliance, flexible resources and a competent partner, we continue to invest in and expand our portfolio of technologies and resources to add the scientific expertise and capacity needed to support the efficient acceleration of drug development. Global Support for Research and Integrated Drug Development RESEARCH MODELS SERVICES FOR RESEARCH MODELS DISCOVERY, IMAGING AND PRECLINICAL SERVICES CLINICAL SERVICES EARLY RESEARCH Research Models Laboratory Animal Equipment PRECLINICAL DEVELOPMENT Research Animal Diagnostic Services Consulting and Staffing Services Genetically Engineered Models and Services Preconditioning Services Functional and Anatomical Imaging In Vitro and In Vivo Screening Lead Optimization Pharmacology Pharmacokinetics / ADME Pharmacodynamics / Biomarkers Safety Pharmacology IND Enabling Toxicology Genetic Toxicology Pathology Services Bioanalytical Services Strategic / Regulatory Consulting PHASE 0/I Early-Phase Clinical Trials Central Laboratory Clinical Bioanalysis Data Management and Biostatistics CLINICAL TRIALS Subchronic / Chronic Toxicology MARKET PHASE II PHASE III PHASE IV Developmental and Reproductive Toxicology Carcinogenicity Studies BIOPHARMACEUTICAL AND VACCINE SUPPORT SERVICES IN VITRO DETECTION SYSTEMS Viral Safety Vaccine Safety and Manufacturing Cell Line Banking and Characterization Potency, Stability, Bioassay Development In Vivo Biosafety Avian Products and Services Endotoxin and Microbial Detection Products and Services charles river 13 14
9 CRIVER-1 International Toll-Free:
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
BIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
The NIH Roadmap: Re-Engineering the Clinical Research Enterprise
NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before
POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.
POLICY AND PROCEDURES OFFICE OF NEW DRUGS Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics Table of Contents PURPOSE...1 BACKGROUND...2 POLICY...3 ROLES AND RESPONSIBILITIES...4
DMPK: Experimentation & Data
DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
Regulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
SERVICES FOR. Devices and Combination Products
SERVICES FOR Devices and Combination Products How to Contact Us U.S. FACILITIES / CLIENT SERVICES St. Paul 2540 Executive Drive St. Paul, MN 55120 FAX 651.675.2005 Atlanta 1265 Kennestone Circle Marietta,
Global regulatory affairs role in the biopharmaceutical industry
CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global
PPD LABORATORIES CENTRAL LAB: SUPERIOR SERVICE, QUALITY DATA WITHOUT COMPROMISES
PPD LABORATORIES CENTRAL LAB: SUPERIOR SERVICE, QUALITY DATA WITHOUT COMPROMISES PPD Laboratories provides world-class scientific expertise with state-of-the-art technologies supported by a commitment
CLINICAL DEVELOPMENT OPTIMIZATION
PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP
Tuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
Mayo Central Laboratory for Clinical Trials A Division within Mayo Clinical Trial Services
Mayo Central Laboratory for Clinical Trials A Division within Mayo Clinical Trial Services LABORATORY TESTING SERVICES YOUR PARTNER IN LABORATORY MEDICINE The key note of progress in the 20th century is
Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
Overview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
We design talent strategies that accelerate business outcomes.
1 We design talent strategies that accelerate business outcomes. Where there are critical gaps, we build talent from within and attract new talent from the outside. At every level of the enterprise, we
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
Basic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science
Position: Biostatistician Required Experience: At least 5 years This position is responsible for providing broad statistical support in general and biostatistical support specifically, including study
Call 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
Quality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
Cell Discovery 360: Explore more possibilities.
Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle
OPKO Health to Acquire Bio-Reference Laboratories
OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition
Overview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 Plenary of the National Health Council in its 15 th Special Meeting, held on 5 August 1997, in the exercise of its competencies, as set forth
4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
BEST PRACTICES RESEARCH
2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost
Technology and Expertise Add Operational Value to Medical Device Trials
Technology and Expertise Add Operational Value to Medical Device Trials Copyright 2015 Medidata Solutions. Medidata Solutions and other trademarks reserved in the US and globally. Medidata and other marks
Lilly Covance Strategic Alliance From Vision to Results. Adrienne Takacs, PhD Jonathan Koch, MBA
Lilly Covance Strategic Alliance From Vision to Results Adrienne Takacs, PhD Jonathan Koch, MBA Topics 1. Lilly s Challenge... a Partnership Opportunity 2. Our Landmark Agreement 3. A Local Success Story
Non-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
Testing Services for Large Molecule Drug Development
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
Approximate cost of a single protocol amendment: $450,000
Insight brief 34% of protocol amendments are avoidable Approximate cost of a single protocol amendment: $450,000 Improving clinical development in emerging biopharma settings: How model based drug development
U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016)
U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016) Executive Summary October 20, 2015 The Regulatory Science Subcommittee (RSS) of the CDRH
Careers in Laboratory Animal Science. Elton Machholz, Lisa Ngaymsa & Miriam Rose Consulting & Staffing Services Division Germantown, MD
Careers in Laboratory Animal Science Elton Machholz, Lisa Ngaymsa & Miriam Rose Consulting & Staffing Services Division Germantown, MD Backgrounds Miriam Rose BS Animal/Veterinary Science West Virginia
Guidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
An information platform that delivers clinical studies better, faster, safer and more cost effectively
An information platform that delivers clinical studies better, faster, safer and more cost effectively Powering Process & Performance Proactively manage study start-up and execution Risk profile new sites
HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
Guidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
PharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
Pharmaceutical Sciences
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences
Biological importance of metabolites. Safety and efficacy aspects
Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural
Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD
BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
A leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering
Medical Device Solutions Battelle Applied Research Device Development Clinical Research Sustaining Engineering 0 2 Overview Applied Research Device Development Clinical Research Sustaining Engineering
NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
Session 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
Challenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT [email protected] National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
Review of CBER's Current and Planned Post-marketing Safety Practices
Review of CBER's Current and Planned Post-marketing Safety Practices Robert Ball MD, MPH, ScM Director, Office of Biostatistics and Epidemiology (OBE), Center for Biologics Evaluation and Research (CBER),
Graduate Program Objective #1 Course Objectives
1 Graduate Program Objective #1: Integrate nursing science and theory, biophysical, psychosocial, ethical, analytical, and organizational science as the foundation for the highest level of nursing practice.
Effective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations
Effective Outsourcing of Clinical Pharmacology Studies in Europe John Horkulak Executive Director, Eurasian External Clinical Study Operations Key Questions Do clinical pharmacology studies require a different
INVESTIGATOR PROFILE: Heather DeLoid, DVM
INVESTIGATOR PROFILE: Heather DeLoid, DVM Meet Heather DeLoid, DVM Heather DeLoid, DVM, joins Preclinical Translational Services of Wake Forest Innovations as its new Associate Surgical Research Veterinarian.
Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
Strategic Consulting Services
Services 1 Leadership Team Mark Levonyak President [email protected] Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services [email protected] Mobile: 952.373.1405 John Eckardt, MD Chief
Mayo Alliance for Clinical Trials
Mayo Alliance for Clinical Trials A Division within Mayo Clinical Trial Services PROFESSIONAL CLINICAL TRIALS SERVICES ADVANCING PATIENT CARE THROUGH SCIENTIFIC DISCOVERY It is a great thing to make scientific
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
Catalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
GLOBAL CORPORATE SERVICES
GLOBAL CORPORATE SERVICES ALIGNING CBRE s Global Corporate Services (GCS) is the world leader in commercial real estate services. As the top real estate services provider named to the Global Outsourcing
Guidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
CTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY
NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results.
The Aptuit Center for Drug Discovery & Development Verona, Italy Uncommon Expertise. Exceptional Results. 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise,
Accenture Accelerated R&D Services:
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Accenture Accelerated R&D Services: Pharmacovigilance Services Overview At our company, we are focused on improving lives
through advances in risk-based
Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform
Rochester BioVenture Center November 14th
Rochester BioVenture Center November 14th Calvert Holdings, Inc. Established in 1996 Parent company for several subsidiaries Focus: health care services and investments Corporate HQ located in Cary, NC
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
Transforming study start-up for optimal results
Insight brief Transforming study start-up for optimal results A holistic, data-driven approach integrating technology, insights and proven processes to position clinical trials for ultimate success Up
GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 19 to 23 October 2009 GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) World Health Organization 2009 All rights
MEDICAL DEVICE & DIAGNOSTICS
to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,
Roche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
PEOPLE > SCIENCE > SOLUTIONS
PEOPLE > SCIENCE > SOLUTIONS Our difference Our foundation Our focus ANALYTICAL CHEMISTRY & MATERIALS CHARACTERIZATION EFFICACY (Functional testing) BIOCOMPATIBILITY (in vivo & in vitro toxicology) CLINICAL
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
Valentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
Global Contract Research Organization (CRO) Industry: Overview and Trends, 2008
A Service of Indigo Research A Cipher www.indigoresearch.com Global CRO Market 2005- $15 Billion Global Contract Research Organization (CRO) Industry: Overview and Trends, 2008 Published April 2008 CRO
From Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace
Novartis Investigator Initiated Trials (IITs) Guidelines
Novartis Investigator Initiated Trials (IITs) Guidelines Introduction and background As part of our commitment to delivering innovative therapies to patients worldwide, Novartis believes in the need to
Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update
Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated
the central lab of choice for investigative sites and sponsors www.labconnectllc.com
the central lab of choice for investigative sites and sponsors www.labconnectllc.com Overview The LabConnect difference. LabConnect begins by developing a uniquely tailored laboratory services plan for
